Weekly Docetaxel as Second-Line Therapy for Patients with Advanced Breast Cancer Resistant to Previous Anthracycline Treatment

Abstract

This phase II trial evaluated the efficacy and toxicity of weekly docetaxel as treatment of advanced metastatic breast cancer patients resistant to prior anthracycline chemotherapy. After the first 18 patients, the initial dose (40 mg/m2, 30-min i.v. infusion for 6 consecutive weeks, followed by 2-week rest) was reduced to 36 mg/m2 in the remaining 17 patients due to the incidence of toxicity (28% grade 3-4 asthenia). Overall response rate was 34% (95% CI, 19-50): two complete (6%) and ten partial responses (28%) were found. The median duration of response was 6.8 months, the median time to disease progression was 8.4 months, and the median overall survival was 13.6 months (median follow-up of 11.4 months). Neutropenia was the only severe hematologic toxicity (17% of patients), whereas asthenia, nail, ocular and skin disorders were the most common nonhematologic toxicities. Only one death during further follow-up was related to toxicity (caused by pulmonary fibrosis). In conclusion, we found weekly docetaxel to be an active and safe chemotherapy regimen for patients with metastatic breast resistant to previous anthracyclines. This weekly regimen caused minimal myelosupression, while retaining significant activity against advanced breast cancer. Both factors provide attractive possibilities for the development of combination therapies incorporating weekly docetaxel. Nevertheless, the number of patients receiving either dose (40 and 36 mg/m2) which we studied is low and our results require confirmation on larger groups of patients.

The Synthesis of a Multiblock Osteotropic Polyrotaxane by Copper(I)‐Catalyzed Huisgen 1,3‐Dipolar Cycloaddition

“…After purification by precipitation and LH-20 column separation, NMR and SEC analysis verified 7 to be highly pure, but with a small amount of acetyleneterminated PEG dimer present from phosgene cross-linking. ALN-a-CD was then threaded onto 7, as shown in Scheme 2, forming a pseudopolyrotaxane (8). This was achieved by adding ALN-a-CD to a concentrated aqueous solution of 7 and sonicating for 30 min at room temperature.…”

“…[6][7] Docetaxel (Taxotere) chemotherapy for the treatment of cancer that has metastasized to bone can result in a number of adverse effects, including neutropenia, alopecia, arthalgia, myelosuppression, etc. [8][9][10][11] A method to improve…”

A Dose-Escalation Study of SAR3419, an Anti-CD19 Antibody Maytansinoid Conjugate, Administered by Intravenous Infusion Once Weekly in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

“…development of peripheral neuropathy. Aside from the neurotoxicity, eye disorders are also commonly described with potent tubulin poisons (43)(44)(45)(46). The reversible corneal toxicity associated with blurred vision, which appeared to be a potential safety issue in the SAR3419 FIM study is now controlled and limited to one grade 1 event of blurry vision with the qw/q2w schedule.…”

A literature-based meta-analysis taxane-based doublet versus single-agent taxane chemotherapy in patients with advanced breast cancer

“…Docetaxel is also approved for patients who have had prior therapy and is one of the most active single cytotoxic agents for metastatic disease (Trudeau et al 1996;Chan et al 1999). Docetaxel yielded responses in 30-40% of pretreated MBC patients, with a median TTP of around 7 months (Jackisch et al 2000;Ramos et al 2003;Mey et al 2003;Maisano et al 2003;Kuroi et al 2003;Burstein et al 2000;Aihara et al 2002;Hainsworth et al 2001;D'Hondt et al 2004).…”